The Future of CAR-T Therapy: Can CAR-T Cure CLL?
Tuesday, November 17, 2020
2:00 PM ET / 1:00 PM CT / 12:00 PM MT / 11:00 AM PT (Duration 60 minutes)
CAR-T is a revolutionary therapy in CLL and other blood cancers. As part of the team led by Dr. Carl June at U. Penn, Dr. Joe Fraietta’s translational research has taken CAR-T from an exciting possibility to a lifesaving “living drug”. Don’t miss this opportunity to be able to learn about the latest CAR-T research and to ask your questions of one of CAR-T’s most innovative pioneers.
Co-founder and Communications Director
Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd
Executive Vice President and Chief Medical Officer
As a post-doctoral fellow under the tutelage of Dr. Carl June at the University of Pennsylvania, Dr. Fraietta developed novel approaches for the treatment of cancer through genetic modification of T lymphocytes that contributed to the initiation of multiple clinical trials and U.S. Food and Drug Administration (FDA) approval of the first CAR T cell therapy. In 2015, Dr. Fraietta assumed the directorship of a research laboratory in the first-of-its-kind Center for Advanced Cellular Therapies where his group led initiatives to interrogate CAR T cell infusion products for key biomarkers and mechanisms of potency, with the objective of predicting clinical responses to adoptive cell therapies. He now directs the Tumor Immunotherapy Laboratory as a faculty member in the same center.
This program was made possible by the support of Adaptive Biotechnologies, Bristol Meyers Squibb, Genentech, and Novartis.